#1 Clinical Trials Search in Europe

Tramazoline Hydrochloride

This article discusses a clinical trial exploring the potential benefits of using a nasal spray containing Tramazoline Hydrochloride and Dexamethasone in patients with Obstructive Sleep Apnea (OSA). The study aims to determine whether preventing nasal obstruction during sleep can improve breathing patterns and reduce the number of apnea/hypopnea events in OSA patients with normal nasal resistance.

Table of Contents

What is Tramazoline Hydrochloride?

Tramazoline Hydrochloride is a medication that belongs to a class of drugs called imidazoline derivatives. It is primarily used as a nasal decongestant, which means it helps to reduce swelling and congestion in the nasal passages. In the context of the clinical trial discussed here, Tramazoline is being studied in combination with dexamethasone, a corticosteroid medication that helps reduce inflammation[1].

Overview of Obstructive Sleep Apnea

Obstructive Sleep Apnea (OSA) is a sleep disorder characterized by repeated episodes of complete or partial blockage of the upper airway during sleep. This can lead to pauses in breathing, reduced oxygen levels, and disrupted sleep. OSA is often associated with loud snoring, daytime sleepiness, and other health complications[1].

Tramazoline Hydrochloride in OSA Treatment

The clinical trial is investigating the use of Tramazoline Hydrochloride in combination with dexamethasone as a potential treatment for OSA. The researchers hypothesize that by preventing increased nasal resistance (congestion) during the night, this combination might:

  • Alter breathing route patterns
  • Decrease the number of apnea and hypopnea events (pauses or shallow breathing episodes)
  • Potentially improve OSA symptoms in patients with normal nasal resistance when awake[1]

Clinical Study Design

The study is designed as a randomized, double-blind, placebo-controlled, cross-over trial. This means:

  • Randomized: Participants are randomly assigned to different treatment groups
  • Double-blind: Neither the participants nor the researchers know who is receiving which treatment
  • Placebo-controlled: Some participants receive an inactive substance (placebo) for comparison
  • Cross-over: Participants will receive both the active treatment and placebo at different times during the study[1]

The study involves four assessments over several weeks, including overnight sleep studies (polysomnography) and measurements of breathing patterns and nasal resistance[1].

Potential Benefits of Tramazoline

The researchers hope that using Tramazoline Hydrochloride with dexamethasone might:

  • Prevent nocturnal nasal obstruction
  • Decrease oral and oro-nasal breathing, which is associated with more apnea events
  • Reduce the number of apnea and hypopnea events
  • Improve overall sleep quality for OSA patients[1]

How Tramazoline is Administered

In this study, Tramazoline Hydrochloride is administered as a nasal spray in combination with dexamethasone. Participants use the spray for one week during certain phases of the study. The effects are then measured through sleep studies and other assessments[1].

It’s important to note that this is a clinical trial, and the use of Tramazoline Hydrochloride for OSA is still being investigated. Patients should not use this medication for OSA without proper medical supervision and guidance[1].

Aspect Details
Study Title Randomized Placebo-controlled Cross-over Trial of the Effect of Nasal Tramazoline With Dexamethasone in Obstructive Sleep Apnoea Patients
Primary Objective To investigate if preventing nasal obstruction can alter breathing patterns and reduce apnea/hypopnea events in OSA patients with normal nasal resistance
Study Design Randomized, double-blind, placebo-controlled, cross-over trial
Intervention Nasal spray containing Tramazoline Hydrochloride (decongestant) and Dexamethasone (corticosteroid)
Control Placebo nasal spray (0.9% sodium chloride solution)
Primary Outcome Change in Apnea-Hypopnea Index (AHI)
Key Measurements Overnight polysomnography, breathing route patterns, nasal resistance
Duration Four assessments over several weeks, including a two-week washout period

FAQ

  • What is the purpose of this clinical trial? The trial aims to investigate whether preventing nasal obstruction during sleep using a combination of Tramazoline Hydrochloride (a decongestant) and Dexamethasone (a corticosteroid) can improve breathing patterns and reduce sleep apnea events in patients with Obstructive Sleep Apnea who have normal nasal resistance when awake.
  • Who can participate in this study? The study includes patients with Obstructive Sleep Apnea (AHI>10 events/h) who have normal nasal resistance. Exclusion criteria include recent upper airway surgery, central apneas, current treatment with nasal decongestants or steroids, respiratory tract diseases, nasal allergies, and smoking.
  • How is the study designed? The study uses a randomized, double-blind, placebo-controlled, cross-over design. Participants undergo four assessments over several weeks, alternating between using the Tramazoline-Dexamethasone nasal spray and a placebo (saline solution), with a washout period in between.
  • What measurements are taken during the study? The study involves overnight polysomnography (sleep study) to measure sleep patterns and breathing, assessment of breathing route patterns (oral, nasal, oro-nasal), and measurement of nasal resistance.
  • What is the main outcome being measured? The primary outcome measure is the Apnea-Hypopnea Index (AHI), which indicates the severity of sleep apnea by counting the number of apnea and hypopnea events per hour of sleep.

Ongoing Clinical Trials on Tramazoline Hydrochloride

  • Study on Docetaxel and Carboplatin-Docetaxel Combination for Prostate Cancer Patients Progressing After Olaparib Treatment

    Not yet recruiting

    2 1 1 1
    Investigated diseases:
    Investigated drugs:
    Italy

Glossary

  • Obstructive Sleep Apnea (OSA): A sleep disorder characterized by repeated episodes of complete or partial blockage of the upper airway during sleep, leading to pauses in breathing or shallow breaths.
  • Tramazoline Hydrochloride: A nasal decongestant that helps to reduce swelling in the nasal passages, making it easier to breathe through the nose.
  • Dexamethasone: A corticosteroid medication that helps to reduce inflammation in the nasal passages.
  • Apnea-Hypopnea Index (AHI): A measure used to indicate the severity of sleep apnea, calculated by the number of apnea and hypopnea events per hour of sleep.
  • Polysomnography: A comprehensive sleep study that records brain waves, blood oxygen levels, heart rate, breathing, and eye and leg movements during sleep.
  • Nasal resistance: The degree of difficulty in breathing through the nose, which can be measured using specialized equipment.
  • Rhinomanometry: A test used to measure nasal airflow and the air pressure inside the nose.
  • Placebo: An inactive substance (in this case, saline solution) used as a control in the study to compare with the active treatment.
  • Cross-over design: A type of clinical trial where participants receive both the active treatment and placebo at different times, allowing for comparison of effects within the same individual.
  • Washout period: A period of time between different treatments in a study, allowing the effects of the previous treatment to wear off before starting the next one.

References

  1. https://clinicaltrials.gov/study/NCT01601509